Loading clinical trials...
Loading clinical trials...
A Randomized, Blinded, Active-controlled Non-inferiority Study of the Efficacy and Safety of OX219 for the Induction of Treatment of Opioid Dependence
Conditions
Interventions
Buprenorphine/naloxone sublingual tablets
Buprenorphine
Locations
14
United States
Birmingham, Alabama, United States
Haleyville, Alabama, United States
National City, California, United States
Oceanside, California, United States
Jacksonville, Florida, United States
Maitland, Florida, United States
Start Date
June 1, 2013
Primary Completion Date
January 1, 2014
Completion Date
January 1, 2014
Last Updated
May 10, 2017
NCT05651516
NCT05505227
NCT05657106
NCT05903495
NCT06862752
NCT05803603
Lead Sponsor
Orexo AB
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions